Day One
WEDNESDAY, MARCH 27, 2019
Day Two
THURSDAY, MARCH 28, 2019
08.00 Registration & Coffee
08.50 Chair’s Opening Remarks
Addressing Knowledge Gap in Immune Tolerance Induction by Connecting the Dots Between Transplantation, Allergies & Autoimmune Diseases
09.00 Antigen-Specific T Cell Profiles as Therapeutic Targets in Allergy and Autoimmune Disease
Synopsis
- High-dimensional phenotyping identifies distinct antigen-specific T cell profiles using peripheral blood from patients with allergy and autoimmune diseas
- Deletion, deviation, anergy, and exhaustion are potential tolerogenic outcomes of therapy
- Tracking antigen-specific T cells during therapy may be a surrogate for clinical response
09.30 Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases
Synopsis
- A review of different approaches for induction of antigen-specific immunotherapy
- A report on recent clinical trials of the approach for immunotherapy of autoimmune diseases and
- A discussion on the potential for combination approaches to promote antigenspecific immunotherapy
10.00 Antigen Specific Approaches to Food Allergy & Immunogenicity
Synopsis
- Inducing tolerance without immune suppression by harnessing nanoparticle technology
- Proof of principle data for Peanut Allergy
- Proof of principle data for Recombinant Proteins
10.30 Speed Networking & Morning Refreshments
11.30 Protection from Childhood Allergies & Inflammatory Bowel Disease
Synopsis
- Prevention of allergic and autoimmune diseases in environment rich microbial exposure
- Potential mechanisms of preventive approach
- Translational aspects and considerations
12.00 Anti-Drug Antibody Responses: Past, Present & Future
Synopsis
- Review the history of ADA responses
- Review the present state of ADA responses
- Discuss the future state of ADA responses
12.30 Antigen-Specific Tolerance for Transplantation
Synopsis
- A top-down approach can be used to overcome the complexity of alloantigens for transplantation tolerance
- Multiple parallel mechanisms involving both innate and adaptive immune cells are implicated for transplantation tolerance
- B cells play a critical role in tolerance resistance in pre-sensitized hosts
13.00 Networking Lunch
Identification & Validation of Novel Targets & Mechanism of Actions for Antigen-Specific Immune Tolerance Induction Antoon Van
14.00 Targeted Antigen Delivery to the Liver via Synthetic Glycosylation Induces Robust Antigen-Specific Tolerance
Synopsis
- Active targeting domains deliver antigen to tolerogenic pathways in the liver, and induce robust antigen-specific tolerance in both mouse and non-human primate models of immunity
- Our technologies are translational, in that the mechanisms induced are consistent with unmet clinical needs, and our molecules are developable
- Discuss potential approaches to de-risk MoA’s in higher-order species, and consider their value
14.30 Antigen-Specific Tolerance Induction in Rheumatoid Arthritis
Synopsis
- What are the opportunities and challenges of antigen-specific tolerance induction in a systemic inflammatory autoimmune disease?
- How does the autoimmune induction phase differ from the inflammatory effector phase in rheumatoid arthritis and what are the implications for therapeutic tolerising strategies?
- What type of immunomonitoring could contribute to evaluation of the outcome of tolerising strategies in rheumatoid arthritis?
15.00 Target Identification in Immune-Mediated Disorders Including Autoimmune Diseases, Allergies, Anti-Drug Responses & Tumor Immunology
Synopsis
• Unbiased and systematic identification of target antigens for T cells using combinatorial chemistry and bioinformatics
• Identification of disease-relevant T cells in autoimmune diseases
• How does the autoimmune T cell response relate to recognition of foreign antigens as triggers?
15.30 Afternoon Refreshments & Poster Session
Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies
16.00 TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis
Synopsis
- TOL2 treatment modalities
- Tolerance induction and maintenance using TOL2
- Preclinical development of TOL2
16.30 Engineering Red Blood Cells for Immune Tolerance Using Cell Squeeze® Technology
Synopsis
- The SQZ process efficiently delivers antigen into red blood cells (RBCs) and primes cells for rapid clearance in the liver and spleen
- SQZ’d RBCs reduce CD4+ and CD8+ T cell responses against model antigens and human autoantigens
- SQZ’d RBCs delay or prevent onset of T1D in adoptive transfer model
17.00 Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?
Synopsis
- What does it take to achieve a robust proof-of-concept for antigen-specific immune tolerance induction strategies in complex auto-immune mediated diseases?
- Delivering on the hype and investment thus far – how to translate promising science and clear opportunity into safe and effective antigen-specific tolerance inducing therapeutics?
- The most promising route to funding: how to secure funding, through cross-industry collaborations, to fuel early clinical trial studies and beyond?
